The third-generation NOD/LtSz-scid/IL2Rγ null (NOD/SCID IL2Rγ null ) mouse represents a significantly improved xenograft model allowing high levels of human leukocyte engraftment over extended follow up. One remaining limitation of this mouse model, however, is the low level of circulating human erythrocytes. We established a practical ex vivo erythroid culture system of xenograft marrow progenitors to enrich for human erythroid progeny. At various time points after transplant, erythroid cells were easily assayed after 17 days of ex vivo culture of xenograft marrow, with nearly all nucleated cells of human origin and approximately 60% human GPA or CD71 positive. We then transplanted cord blood CD34 + cells marked with a lentiviral vector encoding green fluorescent protein (GFP). Three months later, ex vivo culture of xenograft marrow progenitors showed 41.3% of the cultured erythroid cells were positive for GFP and human CD71, and 56.2% were positive for GFP and human GPA, similar to that of circulating leukocytes at the same time point. Next, G-CSF mobilized peripheral blood CD34 + cells from a sickle cell trait subject were infused in this mouse model to determine if the hemoglobin pattern could be modeled. CD34
INTRODUCTION
tioning with total body irradiation (27) . While sufficient numbers of human leukocyte can be achieved, circulating human erythrocytes in the xenograft peripheral The xenograft mouse model is an attractive tool to query the long-term repopulating potential of steadyblood remain low. Ishikawa et al. previously showed that in xenografted state or modified human hematopoietic stem cells (HSC). The recently developed NOD/SCID IL2Rγ null mouse newborn NOD/SCID IL2Rγ null mice, human red cells were detectable in the peripheral circulation at very low model has several advantages including a longer life span, a much reduced risk of developing malignancy, levels, and human erythroid progenitors were present at 9.5% in the bone marrow (BM) 3 months posttransplant and very low numbers of murine T, B, NK, and mast cells. As a result, higher human cell engraftment can (11). In our model using 7-10-week-old mice, human glycophorin A (GPA) positive erythrocytes were only be accomplished than with previous NOD/SCID mouse models (9, 26, 31) . Our group has established an alternadetectable in peripheral blood after intraperitoneal injection of human holo-transferrin immediately after transtive to irradiation conditioning regimen using parenteral busulfan that achieves high-level human cell engraftplantation. These human red cells were present for about 3-4 weeks with the highest level at 0.1% (7) . There ment at low mortality compared to conventional condi- were no human red cells circulating long term after the Isolex 300i automated immuno-magnetic system (Nexell, Miltenyi, Auburn, CA). transplantation, after human red cell infusion, or after splenectomy. The lack of human red cell output may NOD/SCID IL2Rγ null Mice Transplantation result from one or more of several possibilities: differences in the erythroid stress response (24) , low globin Busulfan (Busulfex, Otsuka Pharmaceutical, Rockville, MD) was diluted with phosphate-buffered saline gene and protein expression (15,28), lack of humanspecific cytokines (19), species differences between hu-(PBS, Biofluids, Rockville, MD) to deliver 35 mg/kg in a final volume of 200-500 µl and was injected into reman and murine transferrin, or other anti-human inhibitory signals.
cipient mice intraperitoneally at least 24 h prior to the cell infusion. CB CD34 + cells (2 × 10 6 ) or PB CD34
+
In this report, we have built upon our prior experience with human cell output in this NOD/SCID IL2Rγ null cells (2 × 10 6 ) were infused intravenously via the tail vein as previously described (8) . mouse model using ex vivo culture of xenograft marrow for human erythroid differentiation. This approach using Lentiviral Vector Preparation and Transduction common transplantation and cell culture techniques has allowed us to overcome the limitation of human red cell Self-inactivating (SIN) human immunodeficiency virus 1 (HIV1) vector was prepared as previously dereconstitution in this model. scribed (6 , ME) containing SCF, FLT3L, and TPO (all at 100 ng/ml, and have been reported elsewhere (10,26). Mice were R&D Systems, Minneapolis, MN) in CH-296 (Retro-7-10 weeks old at the time of transplant. Mice were Nectin, Takara-shuzo, Japan)-coated plates for 24 h and cared for according to a protocol approved by the Anithen transduced with these vectors at a multiplicity of mal Care and Use Committee of the National Institute infection (MOI) of 50. Four days later, the GFP expresof Diabetes and Digestive and Kidney Diseases sion of transduced CB cells was evaluated by FACS (NIDDK) at the National Institutes of Health (NIH).
Calibur.
Human Hematopoietic Cell Preparation
Flow Cytometric Analysis for Donor Chimerism Cord blood (CB) cells were obtained from healthy and Leukocyte Subsets volunteers postpartum after written informed consent using a protocol approved by the NIDDK Institutional BM was harvested as previously described (8, 22) and suspended in DMEM with 0.1% bovine serum albumin Review Board (IRB). Mononuclear cells (MNC) were obtained after density-gradient centrifugation using Fi-(BSA, Roche, Basel, Switzerland). BM and PB cells were stained with fluorescein isothiocyanate (FITC)-coll-Paque Plus (Amersham Biotech, Piscataway, NJ) and red blood cells (RBCs) were removed using ammoconjugated anti-human CD45 and PE-conjugated antimouse CD45; human leukocyte subsets were also nium chloride potassium (ACK) lysis buffer (Quality Biological Inc, Gaithersburg, MD). CD34 enrichment was stained with one of the following PE-conjugated antibodies: CD3, CD14, CD16, CD20, CD41, and CD56. performed using CD34 biotinylated antibody and streptavidin microbeads (Miltenyi Biotec, Auburn, CA).
Red blood cells were stained with anti-mouse TER119-FITC and anti-human glycophorin A (GPA)-PE (CD235a); Cells were passed through the positive selection column twice, and their purity assessed by flow cytometry using erythrocyte subsets were stained with human CD45-FITC and CD71-PE. All antibodies were purchased phycoerythrin (PE)-conjugated anti-human CD34 antibody (clone 563) on a FACS Calibur (all BD Bioscifrom BD Biosciences. For the evaluation of GFPmarked human BM cell engraftment for the mice, we ences, San Jose, CA).
Peripheral blood CD34 + cells (PB CD34 + ) were obstained with anti-human CD45-PE. tained from healthy adult volunteers using a protocol Ex Vivo Culture of Progenitors for Human approved by the NIDDK IRB (12). Briefly, volunteers
Erythroid Differentiation received 5 days of 10 µg/kg recombinant human (rHu) granulocyte colony-stimulating factor (G-CSF, Amgen, To obtain erythroid output in vitro, we modified previously described erythroid culture methods (3,14,18, Thousand Oaks, CA). On day 5 of mobilization, PB CD34 + cells were collected by one 12-15-L leukapher-20,29). In the first 3 days (Fig. 1 ), mouse bone marrow (BM, 2 × 10 7 cells), human CB CD34 + (1-2 × 10 6 cells), esis, and CD34-positive selection was performed using 
or PB CD34
+ cells (1-2 × 10 6 cells) were cultured in 10 µl of Hemolysate Reagent (Helena Laboratories) and run on Titan 3 cellulose acetate membranes (Helena six-well plates in 5 ml of DMEM containing 10% fetal bovine serum (FCS) (Hyclone, Thermo Scientific, Laboratories) at 270 volts for 40 min. After electrophoresis, the membrane was stained in Ponceau S (Helena UT), 2 mM glutamine with penicillin/streptomycin (Invitrogen, Carlsbad, CA), 100 ng/ml of rHu stem cell facLaboratories) for 5 min and washed with 7.5% acetic acid (Sigma) five times and ethanol five times. tor (SCF), and 10 ng/ml of rHu interleukin-3 (IL-3) (both R&D systems) at 37°C in 5% CO 2 . This cytokine
Mass Spectrometry Analysis of Hemoglobin Subtypes combination preferentially differentiated human cells. In
The products from erythroid culture were analyzed the next 7 days, nonadherent cells were collected and for protein content by mass spectrometry. Human GPAresuspended in 20 ml of media specific for erythroid positive cells were pelleted, washed twice, and lysed differentiation from a modified protocol containing Dulwith water, frozen at −20°C for 5 min, and thawed at becco's modified essential media (DMEM, Mediatech, 37°C for 5 min. Proteins were analyzed using tandem Herdon, VA), 30% FCS, 2% BSA, 10 −5 M β-mercapto-HPLC-mass spectrometry (MS). Mass from eluted pepethanol, 10 −6 M dexamethasone, 0.6 mg/ml human holotides was queried in the Mascot database, and searched transferrin (Sigma-Aldrich, St. Louis, MO), 2 mM glutafor human hemoglobin variants. mine with penicillin/streptomycin (Invitrogen), 100 ng/ ml of SCF, 1.25 ng/ml of transforming growth factor-β Statistics (TGF-β, R&D Systems) in the medium, and 5 U/ml rHu All measures of variance are presented as standard erythropoietin (EPO, Amgen), in a 75-cm 2 flask at 37°C errors of the mean (SEM). Statistical analyses were perin 5% CO 2 . In the final 7 days, the nonadherent cells formed using Student's t-test with a value of p < 0.05 were again collected and resuspended in the same erydeemed significant. throid-specific media but without TGF-β.
RESULTS

Hemoglobin Determination by Hemoglobin Electrophoresis Human Erythroid Cells Can Be Cultured From Hemoglobin electrophoresis was performed accord-
the Marrow of Humanized Mice ing to the manufacturer's procedures (Helena Laboratories, Beaumont, TX) (4). To determine the hemoglobin When murine peripheral blood was directly assayed periodically after transplantation, there was <1% human content from red cells, RBC pellets were lysed with water, frozen at −20°C for 5 min, and thawed at 37°C for CD71 + or human GPA + cells up to 3 months posttransplant (data not shown). We then decided to harvest BM 5 min. Then 15 µl of the supernatant was mixed with cells from an NOD/SCID IL2Rγ null mouse 4 months after
GFP Marking Is Present Among Erythroid Progeny After Ex Vivo Culture of Humanized Murine BM transplant with human PB CD34
+ cells, and culture them in human erythroid-specific media. In the beginning of the ex vivo culture, the BM cell pellet after red cell lysis To test if this transplantation model could be employed to model gene therapy applications, human CB appeared white or gray, became visibly hemoglobinized at day 10, and progressed to a more red color by day 18 CD34 + cells were transduced by a lentiviral vector encoding GFP at a MOI of 50. The in vitro transduction ( Fig. 2A) months posttransplant (data not shown). However, when cells 3 months posttransplant was similar in the PB of sickle cell trait recipients and control recipients: 13.1 ± BM was collected 3 months posttransplant in one representative mouse, 70.2% were positive for both GFP and 8.4% versus 13.9 ± 10.0%, respectively. At 1 and 3 months posttransplant, BM cells were harvested from human CD45 (Fig. 3A) . After 18 days of ex vivo culture, GFP and human CD45 + cells was enriched to one representative mouse from each group and cultured ex vivo. After 18 days of human erythroid differentia-79.2% (Fig. 3B-D) ; GFP and human CD71 + , 41.3% (Fig. 3E) ; and GFP and human GPA + , 56.3% (Fig. 3F) . tion, the hemoglobin composition was assessed by electrophoresis (Fig. 4) . Adult hemoglobin (HbA) and sickle We then sorted human CD71 + or GPA + cells by using the Miltenyi magnetic selection system and confirmed hemoglobin (HbS) were detected both 1 and 3 months after transplant, and the pattern was similar to that dean almost 100% enrichment by flow (data not shown). These experiments indicated that the genetically modirived from sickle trait product cultured pretransplant. Interestingly, a significant amount of fetal hemoglobin fied human CD34
+ cells could engraft in the murine BM, and maintain the capability to differentiate to human er-(HbF) was also present at both time points, likely a reflection of the culture conditions. ythroid cells ex vivo with human-specific cytokines. 
Recapitulation of Sickle Cell Trait in NOD/SCID Recapitulation of Hemoglobin Switching
As expected, PB CD34
+ cells produced more HbA, this report, we extend our prior observations and demonstrate that human erythroid progenitors reside long term whereas CB CD34 + cells produced more HbF. The addition of TGF-β did not increase the amount HbF from in the humanized murine bone marrow and can differentiate to sufficient numbers of mature red cells ex vivo in PB CD34
+ or CB CD34 + culture (data not shown). We then transplanted PB CD34 + and CB CD34 + cells to two the presence of human-specific cytokines to allow evaluation of hemoglobin at the protein level. This straightgroups of mice after 35 mg/kg of busulfan conditioning, harvested BM cells at various time points, and cultured forward approach of transplantation, marrow progenitor harvest, and ex vivo culture overcomes one limitation of BM cells ex vivo. The hemoglobin electrophoresis of the ex vivo cultured red cells showed that transplanted the NOD/SCID IL2Rγ null xenograft model and allows for assaying erythroid progeny of human HSCs after ex-PB CD34
+ cells consistently produced more HbA than HbF, and this proportion of HbA to HbF ratio did not tended follow up. Our ex vivo culture system employs common murine change from 3 weeks to 6 months posttransplant (Fig.  5A) . In contrast, transplanted CB CD34 + cells produced transplantation techniques, reagents, and human-specific cytokines. The first 3 days of rHu IL-3 and SCF prefermostly HbF at 3 weeks, but the HbA to HbF ratio gradually reversed, similar to the ratio from PB CD34 + cells, entially enriched human cells. The next 7 days of SCF, EPO, and TGF-β directed the differentiation of erythroid by 6-9 months (Fig. 5B) . The progressive loss of HbF synthesis over 9 months closely mirrors that which is cells: SCF increased erythroblast growth (17, 21, 29) , EPO provided the necessary erythroid cytokine, and observed in the normal hemoglobin switching, which occurs in newborns from 1 to 6 months postnatally.
TGF-β accelerated this entire process (1,2,32). We have previously shown that human holo-transferrin provides DISCUSSION the iron necessary for erythroid production (7), and have incorporated this in the culture cocktail. The last 7 days Humanized mice are a useful tool to assay long-term hematopoietic progenitors, and could reduce the need of SCF and EPO served to further expand the number of mature red cells, which were positive for human for the more cumbersome and expensive large-animal models. We and others have achieved high level in vivo CD71 or GPA. Culturing beyond the 18 days only increased the red cell number modestly; the maximal numhuman cell engraftment in this third-generation NOD/ SCID mouse model, which is sustained beyond [4] [5] [6] ber plateaued between 3 and 4 weeks of culture (data not shown). months and in multiple leukocyte subsets (granulocytes, B and T lymphocytes, and NK cells). However, human
We then tested whether this approach could be combined with genetic modification of progenitor cells to erythroid cells in murine peripheral blood remained low in vivo, despite injection with human cytokines (7). In express GFP using a SIN-lentiviral vector as a model During the process of creating sickle cell trait mice, cells can be cultured using the same system, yielding sufficient quantities or red blood cells for analysis of the we discovered that the ability to make HbF was dependent on hematopoietic progenitor source. While HbF success of the genetic modification strategy at the protein level. The logical next step would be to substitute was detected from culturing PB CD34 + as shown previously, CB CD34 + cells retained substantially higher GFP for a gene of interest, such as β-or γ-globin, and evaluate the amount of globin expressed per vector copy HbF synthetic potential when cultured in vitro (data not shown), or when cultured from xenograft mice shortly in the erythroid compartment.
The usefulness of this xenograft model and ex vivo after transplantation (Fig. 5) . This disparity between CB versus PB CD34 + , however, could not be overcome even human erythroid culture also allowed us to test whether a human erythroid phenotype, such as HbS in red cells, by transplantation or potent cytokine cocktails previously shown to induce HbF, such as SCF or TGF-β. could be reproduced. Our transplantation of G-CSF mobilized PB CD34
+ cells from a sickle cell trait donor The longer CB CD34 + cells remained in the xenograft bone marrow, the lower amount of HbF protein was syndemonstrated that these cells engraft equally well, and that their ability to synthesize HbS was preserved in the thesized. Eventually the HbA/HbF proportion in the CB CD34 + group approached to that of the PB CD34 + group, xenograft bone marrow. Although not a disease model, engraftment of sickle trait HSCs in transplanted NOD/ suggesting that the fetal to adult hemoglobin switch had occurred (30) . The combination of the murine marrow SCID mice should allow testing of genetic modification strategies aimed at correction of the hemoglobinpathies microenvironment, murine cytokines, and/or gene silen- 
